AB Science SA stock analysis
AB Science SA (ABSCF) Stock Price & Analysis
ABSCF Stock Chart & Stats
- Day’s Range
- $1.12 - $1.12
- 52-Week Range
- $1.12 - $1.45
- Previous Close
- $1.12
- Volume
- N/A
- Average Volume (3M)
- 0
- Market Cap
- $66.50M
- Enterprise Value
- $55.79M
- Total Cash (Recent Filing)
- $8.98M
- Total Debt (Recent Filing)
- $4.74M
- Price to Earnings (P/E)
- ―
- Beta
- 0.07
- Next Earnings
- Apr 23, 2027 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Revenue Growth
Recent revenue growth indicates that AB Science is expanding its reported business base, even though the scale remains small. If this trend continues, it could improve operating leverage and provide a stronger foundation for funding development activities over the next several quarters.
Debt Reduction
The substantial reduction in debt lowers fixed financing obligations and removes part of the balance-sheet burden carried in prior years. This improves financial flexibility relative to the earlier structure, although the benefit remains constrained by negative equity and continuing cash consumption.
Pipeline Optionality
A proprietary candidate being investigated across several therapeutic areas gives AB Science multiple potential development paths from one core asset. Progress in more than one indication could broaden future commercialization opportunities and reduce reliance on a single narrow clinical use.
Bears Say
Persistent Losses
Persistent operating and net losses show that the current business has not reached breakeven and that revenue is not yet sufficient to cover its operating base. Continued losses can limit internally funded development, weaken earnings quality, and prolong dependence on external financing.
Negative Equity
Persistently negative shareholder equity is a structural solvency weakness that leaves little balance-sheet protection against further losses. It also restricts financial flexibility, making the company more sensitive to funding conditions while it continues advancing its development programs.
Cash Burn
The return to substantial operating and free-cash-flow burn after a positive 2024 indicates that cash generation is not yet dependable. If this pattern persists, AB Science will need continued access to funding to sustain research, development, and regulatory activities.
AB Science SA News
Ab Science’s Phase 3 ALS Trial: A Key Development for Investors
Ab Science (($ABSCF)) announced an update on their ongoing clinical study. Ab Science is spearheading a pivotal Phase 3 clinical trial titled ‘A Prospective, Multicenter, Randomised, Double-blind, Placebo-controlled, Parallel Groups,
ABSCF FAQ
What was AB Science SA’s price range in the past 12 months?
What is AB Science SA’s market cap?
When is AB Science SA’s upcoming earnings report date?
How were AB Science SA’s earnings last quarter?
Is AB Science SA overvalued?
Does AB Science SA pay dividends?
What is AB Science SA’s EPS estimate?
How many shares outstanding does AB Science SA have?
What happened to AB Science SA’s price movement after its last earnings report?
Which hedge fund is a major shareholder of AB Science SA?
What is the TipRanks Smart Score and how is it calculated?
Company Description
AB Science SA
AB Science S.A. is a pharmaceutical company dedicated to the discovery, development, and commercialization of protein kinase inhibitors for applications in both human and animal health. Its primary drug candidate, masitinib, a tyrosine kinase inhibitor, is currently undergoing late-stage (Phase III) clinical investigations for a range of serious conditions including prostate cancer, pancreatic cancer, amyotrophic lateral sclerosis (ALS), multiple sclerosis, Alzheimer's disease, severe asthma, and mastocytosis. Additionally, masitinib is being evaluated in Phase II clinical trials for the treatment of Covid-19. The company's pipeline also features AB8939, a synthetic microtubule destabilizer aimed at treating acute myeloid leukemia, and AB20001, which is in Phase 2 trials to assess the safety and efficacy of masitinib combined with isoquercetin in hospitalized patients experiencing moderate to severe COVID-19. Masitinib is sold under the brand name Masivet in the European market. AB Science S.A. was founded in 2001 and is based in Paris, France.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Stéphane Ledermann
- Employees
- 33
- Website
- www.ab-science.com
- Address
- 3, Avenue George V, Paris, IF, 75008, FR
AB Science SA (ABSCF) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 2 | 0 | 14 |
| Technical Analysis | 1 | 0 | 3 |
| Moving Averages | 1 | 0 | 11 |









